ICAM-1 and VCAM-1 in human renal allograft rejection

Kidney International
P A HillR C Atkins

Abstract

Light microscopy studies have demonstrated heightened ICAM-1 and VCAM-1 expression in renal allograft rejection in experimental animals and in humans, and administration of ICAM-1 blocking antibodies has been shown to prolong graft survival in nonhuman primates. We used a precise ultrastructural immunogold localization technique to identify the exact sites of expression of ICAM-1 and VCAM-1 in both normal human kidney and in renal allograft rejection. In the normal kidney ICAM-1 is moderately strongly expressed in glomeruli, on the endothelium and parietal epithelium and in the interstitium, on the endothelium of peritubular capillaries, arterioles and small arteries, on fibroblast-like interstitial cells and on the brush border of proximal tubules. In contrast, in normal kidney, VCAM-1 expression is restricted to the parietal epithelium and the basolateral surfaces of a few proximal tubule cells. In allograft rejection, although ICAM-1 expression appears to be increased, its pattern of distribution is similar to that seen in the normal kidney. However, VCAM-I in allograft rejection is widely expressed on the endothelium of peritubular capillaries and arterioles in association with adhesion of mononuclear leukocytes within thes...Continue Reading

References

Dec 1, 1992·Journal of the American Society of Nephrology : JASN·R P Wuthrich
Nov 1, 1992·Journal of the American Society of Nephrology : JASN·D M BriscoeR S Cotran
Jan 1, 1992·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·C B AndersenS Larsen
Sep 1, 1991·Clinical Immunology and Immunopathology·M Patarroyo
Jul 1, 1991·Journal of the American Society of Nephrology : JASN·V E Rubin-Kelley, A M Jevnikar
Sep 1, 1991·Transplant International : Official Journal of the European Society for Organ Transplantation·W MoolenaarF J van der Woude
Aug 2, 1990·Nature·T A Springer
Sep 1, 1989·Transplantation·G A BishopB M Hall
Dec 1, 1989·Kidney International·G A Bishop, B M Hall
Apr 1, 1989·Immunological Reviews·S O WawrykA W Boyd
Apr 1, 1989·Cell and Tissue Research·T KinjoH Nagura
Jan 1, 1994·Springer Seminars in Immunopathology·D J Nikolic-PatersonR C Atkins
Jan 1, 1993·Transplant Immunology·P F HalloranJ Madrenas

❮ Previous
Next ❯

Citations

Mar 26, 2004·Transplantation Proceedings·L C Paul, J H de Fijter
Nov 14, 1997·Trends in Genetics : TIG·S J O'BrienL A Lyons
Jun 10, 2000·Histopathology·C O Bellamy, P S Randhawa
May 7, 1999·Kidney International·A J McLarenK I Welsh
Nov 26, 1999·Kidney International·R SayersD Cosgrove
Apr 16, 1998·Transplantation·S V Fuggle, D D Koo
Aug 26, 2000·Transplant International : Official Journal of the European Society for Organ Transplantation·H KauppinenI Lautenschlager
May 1, 1997·Kidney International·K SolezL D Truong
Aug 10, 2000·Experimental and Toxicologic Pathology : Official Journal of the Gesellschaft Für Toxikologische Pathologie·J KriegsmanG Stein
Sep 11, 2010·Néphrologie & thérapeutique·Hugo WeclawiakNassim Kamar
Feb 26, 2005·Transplant International : Official Journal of the European Society for Organ Transplantation·Manuel Gomez del MoralEduardo Martinez-Naves
Jan 12, 2008·International Journal of Immunogenetics·N TajikT Mousavi
Sep 1, 1996·Renal Failure·G A MüllerJ Markovic-Lipkovski
Apr 4, 2007·The Journal of Immunology : Official Journal of the American Association of Immunologists·Anja SaalbachJan C Simon
Apr 5, 2018·International Journal of Molecular Sciences·Deok-Hoon KongSukmook Lee
Dec 31, 2002·Journal of the American Society of Nephrology : JASN·Robert BlaberRobert Steadman
Nov 30, 2000·Journal of the American Society of Nephrology : JASN·Juha KirveskariRisto Renkonen

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.